No Data
Institutional Investors Control 53% of Novavax, Inc. (NASDAQ:NVAX) and Were Rewarded Last Week After Stock Increased 6.3%
Novavax Analyst Ratings
H.C. Wainwright Maintains Novavax(NVAX.US) With Buy Rating, Maintains Target Price $19
Jim Cramer Is 'Not A Fan' Of Novavax, Says This Tech Stock Is 'Expensive'
Novavax, Inc. (NVAX) Is Attracting Investor Attention: Here Is What You Should Know
Express News | Novavax Inc - Working With FDA on Potential Accelerated Approval